You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SARS-CoV-2 B.1.351

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Covid19 Trial in Australia (SII B.1.351, SII Bivalent, SII B.1.617.2)

Withdrawn
  • Covid19
  • SII B.1.351
  • +2 more
  • Maroubra, New South Wales, Australia
  • +3 more
May 25, 2022

COVID-19 Trial in United States (drug, biological, other)

Active, not recruiting
  • COVID-19
  • Birmingham, Alabama
  • +21 more
Feb 2, 2023

COVID-19 Trial in Worldwide (SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein

Active, not recruiting
  • COVID-19
  • SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1
  • +10 more
  • Birmingham, Alabama
  • +71 more
Jul 11, 2022

COVID-19, COVID-19 Immunisation Trial in United States (mRNA-1273, mRNA-1273.351)

Active, not recruiting
  • COVID-19
  • COVID-19 Immunisation
  • mRNA-1273
  • mRNA-1273.351
  • Decatur, Georgia
  • +3 more
Aug 11, 2022

SARS-CoV2 Infection Trial in Renton (HDT-301)

Active, not recruiting
  • SARS-CoV2 Infection
  • HDT-301
  • Renton, Washington
    Rainier Clinical Research
Jan 16, 2023

SARS-CoV-2 Infection, COVID-19 Trial in United States (BNT162b2, BNT162b2.B.1.351)

Completed
  • SARS-CoV-2 Infection
  • COVID-19
  • BNT162b2
  • BNT162b2.B.1.351
  • Oakland, California
  • +16 more
Feb 17, 2022

LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B

Not yet recruiting
  • SARS-CoV-2
  • +4 more
  • LumiraDx SARS-CoV-2 Ag Ultra
  • LumiraDx SARS-CoV-2 & Flu A/B
  • DeLand, Florida
    Hillcrest Medical Research
Feb 6, 2023

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test

Not yet recruiting
  • SARS-CoV-2
  • +3 more
  • LumiraDx SARS-CoV-2 & Flu A/B
  • Cullman, Alabama
    Cullman Clinical Trials
Mar 16, 2023

COVID-19 Vaccines Trial in Paris (2nd booster with Comirnaty® (Pfizer-BioNTech), CoV2 preS dTM adjuvanted vaccine (B.1.351),

Active, not recruiting
  • COVID-19 Vaccines
  • 2nd booster with Comirnaty® (Pfizer-BioNTech)
  • CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
  • Paris, France
    GH Broca-Cochin-Hôtel-Dieu CIC 1417 Cochin-Pasteur
Jul 7, 2022

Influenza A, Influenza Type B, SARS CoV 2 Infection Trial in Raleigh (Diagnostic Test for identification of influenzas A,

Not yet recruiting
  • Influenza A
  • +3 more
  • Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections
  • Raleigh, North Carolina
    Wake Med
Jun 26, 2023

COVID-19 Trial (NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg))

Not yet recruiting
  • COVID-19
  • NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
  • Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
  • (no location specified)
Aug 4, 2023

SARS-CoV-2 Trial in Islamabad (SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution)

Recruiting
  • SARS-CoV-2
  • SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)
  • 0.9% sodium chloride solution
  • Islamabad, Pakistan
    Sindh Infectious Diseases Hospital & Research Center Dow Univers
Apr 16, 2023

SARS-CoV-2 Infection Trial in Australia (ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001))

Recruiting
  • SARS-CoV-2 Infection
  • ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
  • Kanwal, New South Wales, Australia
  • +5 more
Nov 16, 2022

Respiratory Viral Infection Trial (SARS-COV-2, Influenza and RSV 8-Well MT-PCR Panel, BioFire Respiratory Panel 2.1)

Not yet recruiting
  • Respiratory Viral Infection
  • SARS-COV-2, Influenza and RSV 8-Well MT-PCR Panel
  • BioFire Respiratory Panel 2.1
  • (no location specified)
Jul 13, 2023

SARS-CoV-2 Infection Trial in Beijing (HH-120 nasal spray 1, HH-120 nasal spray 2, Placebo Comparator 1)

Completed
  • SARS-CoV-2 Infection
  • HH-120 nasal spray 1
  • +3 more
  • Beijing, Beijing, China
    Beijing Ditan Hospital,Capital Medical University
Mar 1, 2023

COVID-19, SARS-CoV-2 Trial in Seoul (QTP104 1ug, QTP104 5ug, QTP104 25ug)

Active, not recruiting
  • COVID-19
  • SARS-CoV-2
  • QTP104 1ug
  • +2 more
  • Seoul, Korea, Republic of
  • +1 more
May 24, 2023

SARS-CoV-2 Trial (SARS-CoV-2 variant mRNA vaccine low dose, SARS-CoV-2 variant mRNA vaccine high dose)

Not yet recruiting
  • SARS-CoV-2
  • SARS-CoV-2 variant mRNA vaccine low dose
  • SARS-CoV-2 variant mRNA vaccine high dose
  • (no location specified)
Oct 30, 2022

SARS-CoV2 Infection, Covid19, SARS-CoV-2 Acute Respiratory Disease Trial in Worldwide (BNT162b2, BNT162b2 (B.1.1.7 + B.1.617.2),

Active, not recruiting
  • SARS-CoV2 Infection
  • +3 more
  • BNT162b2
  • +5 more
  • Long Beach, California
  • +34 more
Jan 10, 2023

COVID-19, Vaccine Reaction Trial in Paris (BNT162b2, CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK, CoV2 preS dTM

Active, not recruiting
  • COVID-19
  • Vaccine Reaction
  • BNT162b2
  • +2 more
  • Paris, France
    GH Broca-Cochin-Hôtel-Dieu CIC 1417 Cochin-Pasteur
Jul 7, 2022

SARS-CoV-2 Infection Trial in Baltimore (B/HPIV3/S-6P)

Recruiting
  • SARS-CoV-2 Infection
  • B/HPIV3/S-6P
  • Baltimore, Maryland
    Johns Hopkins Bloomberg School of Public Health
Aug 30, 2023

Viral Dynamics of Omicron in Children

Completed
  • SARS-CoV2 Infection, COVID-19
  • Daily SARS-CoV-2 PCR Testing for 10 days
  • Toronto, Ontario, Canada
    The Hospital for Sick Children
Nov 25, 2022

COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2)

Completed
  • SARS CoV 2 Infection
    • Xi'an, Shaanxi, China
      First Affiliated Hospital of Xian JiaotongUniversity
    Feb 16, 2022

    Covid19 Trial in Cypress (VXA-CoV2-1)

    Completed
    • Covid19
    • VXA-CoV2-1
    • Cypress, California
      WCCT
    Jan 17, 2023

    SARS-CoV-2 Vaccine Tolerability and Clinical Outcome Among

    Completed
    • SARS-CoV2 Infection
    • +3 more
    • IM injection of vaccination (mRNA vaccination)
    • IM injection of vaccination (vector based vaccination)
    • Hildesheim, Niedersachsen, Germany
      Helios Hospital Hildesheim
    Dec 29, 2022

    Sars-CoV-2 Infection Trial in South Africa (Alveavax-v1.2, Janssen Ad26.COV2.S)

    Completed
    • Sars-CoV-2 Infection
    • Bloemfontein, Free State, South Africa
    • +7 more
    May 2, 2023